PRODUCT

Introduction to Boryung
caring for people’s health

Main Products

A guide to Boryung’ main
products.

Products

A guide to all
Boryung’s products.

close

R&D

The Boryung Company,
envisioning a world with a
healthy mankind.

R&D Vision·Strategy

Boryung’ goal is to develop
into a global company.

Pipeline

The research team at Boryung
aims to lead the future of the
pharmaceutical industry.

close

GLOBAL
BUSINESS

An introduction of
Boryung’ global business.

Introduction

The best global company.

CMO

Introducing BRCMO business

Network

50 markets and 150 partners worldwide.

close

PR

An introduction of Boryung ’ value -
Envisioning a healthy mankind.

Advertising

An introduction of video
and printed advertisements of Boryung.

close

Directions

An introduction of Boryung
Pharmaceutical’ value - Envisioning
a healthy mankind.

Directions

An introduction of video
and printed advertisements of Boryung.

close

Financial Information

Summary of Consolidated Statements of Financial Position

(Unit : KRW 1,000,000 / As of December 31, 2023)

Summary of Consolidated Statements of Financial Position
Financial items 2023 2022 2021
Current assets 377,659 338,378 437,314
Non-current assets 537,852 554,008 391,327
Total assets 915,512 892,386 828,641
Current liabilities 201,083 227,483 155,953
Non-current liabilities 165,176 98,486 198,374
Total liabilities 366,259 375,969 354,327
Share capital 34,345 34,345 34,345
Other paid-in capital and Other components of equity 107,468 105,393 104,691
Retained earnings 406,936 376,179 334,827
Total equity 549,253 516,417 474,314

Summary of Consolidated Statements of Comprehensive Income

(Unit : KRW 1,000,000 / As of December 31, 2023)

Summary of Consolidated Statements of Comprehensive Income
Financial items 2023 2022 2021
Revenue 859,626 760,476 627,279
Cost of sales 506,196 453,289 362,342
Gross profit 353,430 307,187 264,937
Selling and administrative expenses 237,877 208,879 184,343
R&D expenses 47,286 41,705 39,146
Operating profit 68,267 56,603 41,448
Finance income 7,098 37,461 11,916
Finance costs 11,834 21,375 5,156
Other income 1,385 2,317 1,377
Other expenses 4,564 11,980 4,320
Share of loss of associates -4,048 -4,154 25,453
Profit before income tax 56,306 58,872 70,718
Income tax expense 16,092 16,934 27,599
Profit for the year 40,213 41,938 43,119
Total comprehensive income for the year 37,293 48,796 44,409

Major financial ratio

(As of December 31, 2023)

Major financial ratio
Financial items 2023 2022 2021
Revenue growth rate 13.04% 21.23% 11.64%
Profit growth rate -4.11% -2.74% 60.53%
ROA 4.45% 4.87% 5.84%
ROE 7.55% 8.47% 10.59%
Debt ratio 66.68% 72.80% 74.70%
Reserve ratio 1184.85% 1095.30% 974.89%
Interest coverage ratio (times) 7.15 9.24 9.26

Analysis on profitability

(As of December 31, 2023)

Analysis on profitability
Financial items 2023 2022 2021
Gross profit margin 41.11% 40.39% 42.24%
R&D investment ratio 6.04% 6.09% 6.64%
Selling and administrative expenses ratio 27.67% 27.47% 29.39%
Operating profit margin 7.94% 7.44% 6.61%
Profit ratio for the year 4.68% 5.51% 6.87%
TOP